MiR-664-3p suppresses osteoblast differentiation and impairs bone formation via targeting Smad4 and Osterix

Area of Science:

• Biochemistry
• Molecular Biology
• Bone Biology

Background:

• Osteoporosis is a bone metabolic disorder increasing fracture risk.
• MicroRNAs (miRNAs) are implicated in regulating osteoblast differentiation and bone mass.
• miR-664-3p was found to be downregulated during osteogenic differentiation.

Purpose of the Study:

• To investigate the role of miR-664-3p in bone homeostasis.
• To identify the molecular targets of miR-664-3p in osteogenesis.

Main Methods:

• In vitro studies using preosteoblast cells (MC3T3-E1).
• In vivo studies with osteoblastic miR-664-3p transgenic mice.
• Target prediction and experimental validation for Smad4 and Osterix (Osx).
• Inhibition of miR-664-3p using antagomirs in an ovariectomy-induced osteoporosis model.
• Serum analysis from osteoporosis patients and normal subjects.

Main Results:

• Overexpression of miR-664-3p inhibited osteoblast activity and matrix mineralization in vitro.
• miR-664-3p transgenic mice showed reduced bone mass due to suppressed osteoblast function.
• Smad4 and Osx were confirmed as direct targets of miR-664-3p.
• Inhibition of miR-664-3p protected against ovariectomy-induced bone loss.
• Serum miR-664-3p levels were significantly higher in osteoporosis patients.

Conclusions:

• miR-664-3p suppresses osteogenesis and bone formation by targeting Smad4 and Osx.
• miR-664-3p is a potential diagnostic biomarker for osteoporosis.
• miR-664-3p represents a novel therapeutic target for treating osteoporosis.